Surfix is redefining POC testing by co-developing customized immuno-based assays in collaboration with partners. With detection sensitivities in the subpicogram/mL range, these advanced assays leverage Surfix’s photonic diagnostics platform to deliver beyond lab-level sensitivity across various sample types. The platform’s flexibility supports an extensive range of POC applications.

Diagnostic success factors

The platform houses multiple features enabling near patient diagnostics. Key are:

> Ultra sensitive: detecting proteins from fg/mL to ug/mL

> High diagnostic accuracy: multiplexing upto 5 biomarkers in one test

> Results in 15 minutes: no return visit needed

> Easy to use small desktop analyzer: suits fully decentralized testing

Expanding the Pipeline

The versatility of Surfix’s photonic diagnostics platform enables applications like:

• • • > Cardiovascular diseases
• > Infectious diseases
• > Neurodegenerative conditions
• > Oncology
• > Inflammation

These advancements underline the platform’s transformative potential for diverse diagnostic challenges. For an in-depth look at our achievements, explore our comprehensive whitepapers. 

Founded in 2011 as a spin-off from Wageningen University & Research (WUR), Surfix initially focused on R&D services for nanocoatings, supporting applications such as biosensors and microfluidic devices. Over the next decade, Surfix’s expertise in nanotechnology laid the foundation for a significant pivot in 2021: start of the development of its groundbreaking photonic diagnostics platform.

Today, Surfix specializes in co-developing tailored POC assays, delivering rapid and precise immuno-based biomarker detection for the POC market.

Building for the Future

The continued evolution of Surfix’s platform is strengthened by the PhotonMed project (Chips JU), a collaborative initiative aimed at accelerating the integration of photonics-based medical devices into healthcare systems. Furthermore, national growth fund programmes nxtGen and PhotonDelta are supporting Surfix with projects to develop technology and the diagnostics platform. Surfix shows versatility in applications via European collaborations through Eurostars. These projects highlights Surfix’s commitment to advancing diagnostics and transforming global health.